VRDN · Viridian Therapeutics, Inc.\DE
$19.18
+0.62 (+3.34%)
At close · Jul 21
Market Cap
$1.98B
Shares
103.07M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$70.85M
+23359.9%
FY2025
Net Income
-$342.6M
-26.9%
FY2025
Gross Margin
26.72%
-30pp
FY2016
Operating Margin
-512.91%
+98505.3pp
FY2025
Diluted EPS
-$5.31
-31.1%
FY2023
Operating Cash Flow
-$276.39M
-19%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $70.92M | $70.85M | $302K | $314K | $1.77M | $2.96M | $1.05M | $4.46M | $8.39M | $4M | $3.48M | $5.71M | $6.48M | $5.49M | |
| — | — | — | — | — | — | — | — | — | — | $2.55M | $2.47M | $3.37M | $2.78M | |
| — | — | — | — | — | — | — | — | — | — | $929K | $3.23M | $3.12M | $2.71M | |
| — | — | — | — | — | — | — | — | — | — | 26.72% | 56.68% | 48.09% | 49.41% | |
| $339.73M | $338.93M | $238.25M | $159.77M | $100.89M | $56.89M | $28.3M | $34.79M | $30.42M | $19.62M | $13.69M | $1M | $347K | $225K | |
| — | — | — | — | — | — | — | — | — | — | $1.67M | $2.56M | $717K | $349K | |
| $77.23M | — | $61.08M | $95M | $35.18M | $25.81M | $13.27M | $11.65M | $11.05M | $10.91M | $6.77M | $7.69M | $6.86M | $1.41M | |
| — | $95.32M | $61.08M | $95M | — | — | — | — | — | — | — | — | — | — | |
| — | $460K | $540K | $522K | $255K | $120K | $239K | $288K | $281K | $308K | $341K | $184K | $144K | $148K | |
| — | — | — | — | — | — | $300K | $2M | — | — | — | — | — | — | |
| $456.62M | $434.24M | $299.34M | $254.76M | $136.08M | $82.69M | $111.43M | $46.44M | $41.47M | $30.54M | $20.46M | $13.73M | $11.19M | $4.51M | |
| — | — | — | — | — | — | — | — | — | — | $15.85M | $13.73M | — | — | |
| -$385.7M | -$363.4M | -$299.04M | -$254.45M | -$134.3M | -$79.73M | -$110.38M | -$41.98M | -$33.08M | -$26.53M | -$16.99M | -$11.19M | -$6.87M | -$197K | |
| — | -512.91% | -99018.21% | -81035.03% | -7579.23% | -2690.79% | -10512.38% | -941.02% | -394.51% | -662.8% | -488.55% | -196.06% | -105.91% | -3.59% | |
| — | -$362.94M | -$298.5M | -$253.93M | -$134.05M | -$79.61M | -$110.14M | -$41.69M | -$32.8M | -$26.22M | -$16.65M | -$11M | -$6.72M | -$49K | |
| $7.86M | $4.95M | $2.2M | $1.33M | $500K | — | — | — | — | — | $95K | $141K | $1.02M | $1.96M | |
| — | $27.4M | $31.6M | $18.24M | — | — | — | — | — | — | — | — | — | — | |
| $25.11M | $20.79M | $29.09M | $16.72M | $4.43M | $315K | $173K | $941K | $1.25M | $403K | $39K | — | — | — | |
| — | $0 | — | — | — | — | — | — | — | — | — | $0 | $0 | — | |
| -$360.59M | -$342.6M | -$269.95M | -$237.73M | -$129.87M | -$79.41M | -$110.72M | -$41.87M | -$32.7M | -$26.51M | -$17.27M | -$11.33M | -$7.89M | -$2.16M | |
| — | -483.57% | -89387.09% | -75711.46% | -7329.23% | -2680.16% | -10544.29% | -938.65% | -389.97% | -662.3% | -496.81% | -198.53% | -121.68% | -39.34% | |
| -$86.65M | — | — | — | — | -$79.41M | -$110.72M | -$41.87M | -$32.7M | -$26.52M | -$17.32M | — | -$7.89M | -$2.45M | |
| -$361.39M | -$342.14M | -$270.3M | -$237.01M | -$130.11M | -$79.56M | -$110.72M | -$41.87M | -$32.71M | -$26.51M | — | — | — | — | |
| USD/shares | — | — | — | -$5.31 | -$4.05 | -$6.66 | -$31.13 | — | — | — | — | — | — | — |
| USD/shares | — | — | — | -$5.31 | -$4.05 | -$6.66 | -$31.13 | — | — | — | — | — | — | — |
| shares | — | — | — | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 1.97M | 1.28M | 40.93K | 35.96K | 150.39K | 13.33K |
| shares | — | — | — | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 1.97M | 1.28M | 40.93K | 35.96K | 150.39K | 13.33K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.03×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $70,000,000 | $0 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| License | $70,000,000 | $0 | $0 | — | — | — |
| Collaboration | $849,000 | $302,000 | $314,000 | — | — | — |
| Collaboration Revenue | — | — | — | — | — | $4,308,000 |
| Reimbursement Revenue | — | — | — | — | — | $4,308,000 |
| Grant | — | — | — | $0 | $315,000 | $153,000 |
| Collaboration Revenue | — | — | — | $2,963,000 | $735,000 | — |
Key facts
CIK
1590750
CUSIP
92790C104
13F (30d)
14 filings
14 filers
Visit website
Investor relations